Table 3.
Comparison of clinical and virological parameters between recipients infected with single or multiple HCMV strains
| Recipients with single-strain infection (n = 9) | Recipients with multiple-strain infection (n = 7) | p value | |
|---|---|---|---|
| Sex male, n (%) | 5 (56) | 4 (57) | 1 |
| Mean age (range), years | 51 (24–63) | 51 (19–62) | 0.633 |
| Donor/recipient HCMV serostatus, n (%) | 0.358 | ||
| D + R + | 4 (44) | 5 (71) | |
| D − R + | 5 (56) | 2 (29) | |
| In vivo T cell depletion, n (%) | 7 (78) | 6 (85) | 1 |
| aGvHD, n (%) | 5 (56) | 3 (42) | 1 |
| Median time to onset of aGvHD (range), days after HSCT | 35 (10–66) | 36 (28–47) | 0.786 |
| Fatal outcome, n (%) | 3 (33) | 2 (29) | 1 |
| Median time to fatal outcome (range), days after HSCT | 254 (211–1445) | 423 (134–711) | 0.8 |
| More than one reactivation episode, n (%) | 4 (44) | 1 (14) | 0.308 |
| DNAaemia detected at day 80, n (%) | 5 (56) | 0 (0) | 0.034 |
| Median HCMV load (range), IU/ml plasmaa | 1680 (303–5790) | 2010 (348–398,000) | 0.374 |
| Median viral load peak value (range), IU/ml | 2550 (463–5790) | 1630 (692–398,000) | 0.918 |
| Median duration of individual antigenaemia episodes (range), days after HSCT | 15 (0–38) | 11 (7–19) | 0.202 |
| Median duration of overall HCMV-antigenaemia (range), days | 25 (0–49) | 14 (9–22) | 0.142 |
| Median antigenaemia peak value (range), pp65 positive cells/400 000 leukocytes | 33 (0–400) | 88 (13–303) | 0.837 |
Bold value indicates statistically significant p values of < 0.05
D donor, aGvHD acute graft-versus-host disease, HSCT haematopoietic stem cell transplantationm, R recipient
aFor all plasma samples with sequence data of the respective group